2007
DOI: 10.1007/s00228-007-0385-2
|View full text |Cite
|
Sign up to set email alerts
|

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

Abstract: Patients with either CYP2C9*2 or CYP2C9*3 show higher risk of over-anticoagulation compared to CYP2C9*1*1 subjects and could benefit from a reduction in the initial warfarin standard dose (e.g., to 2.5 mg/day).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
20
0
1

Year Published

2008
2008
2021
2021

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 26 publications
(23 citation statements)
references
References 30 publications
2
20
0
1
Order By: Relevance
“…In accordance, Asiatics and Africans 1 also had shown a low incidence of both CYP2C9*2 (4%) and CYP2C9*3 (2%) alleles. Similarly, black North 10 and South Americans 22,23 showed low mutation rates of CYP2C9*2 and CYP2C9*3 alleles, 1.0-4.5 and 0.5-3.2 respectively. The frequencies of the CYP2C9*2 (9%) and CYP2C9*3 (7%) found in our epileptic Brazilian population were very close to those found in European populations (Figure).…”
Section: Resultsmentioning
confidence: 97%
See 2 more Smart Citations
“…In accordance, Asiatics and Africans 1 also had shown a low incidence of both CYP2C9*2 (4%) and CYP2C9*3 (2%) alleles. Similarly, black North 10 and South Americans 22,23 showed low mutation rates of CYP2C9*2 and CYP2C9*3 alleles, 1.0-4.5 and 0.5-3.2 respectively. The frequencies of the CYP2C9*2 (9%) and CYP2C9*3 (7%) found in our epileptic Brazilian population were very close to those found in European populations (Figure).…”
Section: Resultsmentioning
confidence: 97%
“…Brazil represents one of World's most heterogeneous populations, as the result of 500 years of extensive interethnic crossover. Until now, just three studies assessed the CYP2C9 polymorphism frequency among Brazilian population [22][23][24] . The genotype analyses revealed that the frequencies of CYP2C9*2 and CYP2C9*3 were 8-9% and 6-7% 22,23 .…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Taube et al [19] proposed that once patients with variant CYP2C9 alleles were stabilized on warfarin therapy, they were no more prone to over-anticoagulation during long-term therapy than patients with the wild-type genotype. However, other data from a recent study by Lima et al [24] in Brazilian patients genotyped for CYP2C9 suggested that patients encoding nonwild-type CYP2C9*2 or *3 alleles are at increased risk for developing out-ofrange INRs for several reasons. These investigators reported that patients with CYP2C9*2 or 3 genotypes were significantly more difficult to maintain at target INR (P = 0.038), with significantly reduced ratio of in range INR measures.…”
Section: Warfarin Mechanism Of Actionmentioning
confidence: 93%
“…A total of six works were included in this review [54][55][56][57][58][59] all of them evaluated the influence of CYP2C9 *2 and *3 alleles and reported lower dose requirements or warfarin sensitivity in individuals carrying these variants. Moreover, the study by Lima et al [59] reported an increased risk for bleeding in patients initiating warfarin therapy (OR: 4.7, 95% CI: 1.4-16.6) compared to subjects carrying CYP2C9 *1/*1. In addition, the rare variants CYP2C9 *5 and *11 were also evaluated [57,58] and the authors showed that together with *2/*3 alleles, the presence of any of these variants affect the warfarin response leading to lower dose requirements.…”
Section: Cyp2c9mentioning
confidence: 99%